Results 101 to 110 of about 44,894 (310)

Clinical Experience With Eliglustat in Children With Gaucher Disease Type 1

open access: yes
American Journal of Medical Genetics Part A, EarlyView.
Erika R. Vucko   +6 more
wiley   +1 more source

Tramadol Co‐Administration with Oxycodone or Hydrocodone Increases Opioid Burden without Improving Postoperative Pain Control

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Tramadol is frequently co‐prescribed with oxycodone or hydrocodone after surgery under the assumption that its dual mechanism of action provides an opioid‐sparing benefit. However, evidence supporting this practice is limited and inconsistent. We conducted a secondary analysis of the multicenter IGNITE ADOPT‐PGx pragmatic trial of patients undergoing ...
Noor A. Nahid   +302 more
wiley   +1 more source

PHARMACOGENETIC FEATURES OF THERAPY OF PATIENTS WITH ATHEROSCLEROSIS

open access: yesАрхивъ внутренней медицины, 2018
The complexity of therapy of lipid metabolism disorders is not only in comorbidity and polypragmasia, but also in predicting a genetically determined response to the treatment.
A. L. Khokhlov   +7 more
doaj   +1 more source

CYP2D6 Polymorphisms in Patients with Porphyrias

open access: yesMolecular Medicine, 2006
The cytochrome P-450 (CYP) isoenzymes, a superfamily of heme proteins which are the terminal oxidases of the mixed function oxidases system, metabolize more than 70% of all clinically approved drugs. The highly polymorphic CYP2D6 isoform metabolizes more than 25% of most common drugs, and the phenotypes of the 70-plus allelic variants range from ...
Jimena Lavandera   +3 more
openaire   +2 more sources

Long‐Acting Therapeutics in Pediatric Health: Bridging Innovation and Access

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Children have distinct therapeutic needs arising from age‐dependent physiology, disease epidemiology, formulation requirements, dosing considerations, and safety vulnerabilities. Despite substantial reductions in childhood mortality over the past three decades, nearly 5 million children under five died in 2023, with infectious diseases continuing to ...
Prajith Venkatasubramanian   +5 more
wiley   +1 more source

Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection [PDF]

open access: yes, 2009
Autoimmune hepatitis (AIH) is a chronic liver disease of unknown etiology, characterized by a loss of tolerance against hepatocytes leading to the progressive destruction of hepatic parenchyma and cirrhosis. Clinical signs for AIH are interface hepatitis
Holdener, Martin
core  

CYP2D6 Predicts Plasma Donepezil Concentrations in a Cohort of Thai Patients with Mild to Moderate Dementia

open access: yesPharmacogenomics and Personalized Medicine, 2020
Monpat Chamnanphon,1 Sorawit Wainipitapong,2 Teeravut Wiwattarangkul,3 Phenphichcha Chuchuen,2 Kunathip Nissaipan,1,4 Weeraya Phaisal,1,4 Sookjaroen Tangwongchai,2 Chonlaphat Sukasem,5 Supeecha Wittayalertpanya,1,4 Andrea Gaedigk,6 Daruj Aniwattanapong,2
Chamnanphon M   +11 more
doaj  

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment [PDF]

open access: yesPharmaceuticals, 2010
Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen.
Ferraldeschi, R.   +1 more
openaire   +5 more sources

Physiologically Based Pharmacokinetic Modeling to Assess Transporter‐Mediated Drug–Drug Interactions in Support of Labeling Recommendations for Zavegepant Nasal Spray

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Zavegepant nasal spray, a calcitonin gene‐related peptide receptor antagonist indicated for acute treatment of migraine with or without aura in adults, is a substrate for organic anion transporting polypeptide 1B3 (OATP1B3), Na+/taurocholate cotransporting polypeptide (NTCP), P‐glycoprotein (P‐gp), and cytochrome P450 3A4 (CYP3A4).
Alice Ke   +8 more
wiley   +1 more source

Possible impact of the CYP2D6*10 polymorphism on the nonlinear pharmacokinetic parameter estimates of paroxetine in Japanese patients with major depressive disorders

open access: yesPharmacogenomics and Personalized Medicine, 2014
Junji Saruwatari,1 Hiroo Nakashima,1 Shoko Tsuchimine,2 Miki Nishimura,1 Naoki Ogusu,1 Norio Yasui-Furukori21Division of Pharmacology and Therapeutics, Graduate School of Pharmaceutical Sciences, Kumamoto University, Kumamoto, Japan; 2Department of ...
Saruwatari J   +5 more
doaj  

Home - About - Disclaimer - Privacy